Please try another search
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix, a device separates sperm from raw semen by electrophoresis process for use in human IVF procedures. In addition, the company’s product pipeline include ROSA, a rapid oxidative stress assay; Samson Device, rapid equine pregnancy prediction assay; SemPort, a system that allows transport of semen; and AI-Port. Further, it provides ambient temperature storage product for human sperm. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
Name | Age | Since | Title |
---|---|---|---|
John Andrew Gowans Seton | 58 | 2018 | Independent Chairman |
Matt Adams | - | 2017 | MD, Director & Company Secretary |
Shadi Mahassel | - | - | Member of Global Advisory Committee |
Simon Pearce | - | - | Member of Global Advisory Committee |
Jonathan Hannam | - | - | Member of Global Advisory Committee |
Ian Charles Bailey | - | 2017 | Non-Independent Director |
Paul Wright | 58 | 2020 | Independent Non-Executive Director |
Robert John Cooke | 67 | 2022 | Independent Non-Executive Chairman |
David Ali | - | 2023 | Acting CEO & Executive Director |
Michael William Atkins | - | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review